The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

Iridoids derived from Valeriana jatamansi Jones alleviates neuroinflammation and blood spinal cord barrier permeability after spinal cord injury by activating the Nrf2/HO-1 signaling pathway ...

Recent advances in glucose management are reshaping our understanding of cognitive decline and dementia prevention. Energy ...

A class of drugs, MDM2 inhibitors, being studied as cancer therapeutics may accidentally damage the protective barriers in the brain and eyes, finds new research in mice.

Each year in the U.S., approximately 2.5 million people suffer traumatic brain injuries (TBIs). About 50,000 of these injuries will result in death, and more than 80,000 will lead to permanent ...

The brain fog that can linger after a bout with COVID is not a new discovery. In fact, much research has linked this ...